Acadia Healthcare Reports Preliminary Court Approval of Derivative Settlement

What Happened
Acadia Healthcare Company, Inc. announced that on September 1, 2026 the U.S. District Court for the Middle District of Tennessee entered a Preliminary Approval Order for a proposed settlement resolving stockholder derivative claims brought nominally on behalf of the Company. The settlement covers claims in four derivative actions (including Solak v. Jacobs and related cases in Delaware Chancery and the Middle District of Tennessee). As required by the order, Acadia attached the Stipulation of Settlement dated July 31, 2026 and a Notice of Pendency and Proposed Settlement to the Form 8-K (Exhibits 99.1 and 99.2).

Key Details

• Preliminary Approval Order issued by the U.S. District Court for the Middle District of Tennessee on September 1, 2026.
• Stipulation of Settlement dated July 31, 2026; Notice of Pendency and Proposed Settlement filed as Exhibits 99.1 and 99.2.
• Derivative actions referenced: Solak v. Jacobs (Del. Ch. Case No. 2021-0163-NAC), Davydov v. Jacobs (3:19-cv-00167 M.D. Tenn.), Beard v. Jacobs (3:19-cv-0441 M.D. Tenn.), and Pfenning v. Jacobs (Del. Ch. Case No. 2020-0915-NAC).
• The filing notes the latter three cases were related to securities litigation previously settled in November 2025; the 8-K does not disclose monetary terms or specific corporate governance remedies.

Why It Matters
This moves the derivative suits a step closer to final resolution, which could reduce legal uncertainty and potential future costs for Acadia if the settlement is ultimately approved. The 8-K does not disclose any payment amounts or financial impact, so investors should watch for further filings that describe settlement terms, any required payments or board/governance changes, and potential accounting or disclosure effects.